Clinical Trials Logo

Esophagogastric Junction Cancer clinical trials

View clinical trials related to Esophagogastric Junction Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05275062 Recruiting - Pancreatic Cancer Clinical Trials

Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma

Start date: February 15, 2022
Phase: Early Phase 1
Study type: Interventional

This is a open-label, single center to determine the efficacy and safety of IM92 CAR-T cells in Patients With advanced gastric/esophagogastric combination adenocarcinoma that has failed at least second-line therapy and advanced pancreatic cancer that has failed at least first-line therapy.

NCT ID: NCT05259696 Recruiting - Breast Cancer Clinical Trials

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

GLIMMER-01
Start date: February 11, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.

NCT ID: NCT04821778 Recruiting - Chemotherapy Effect Clinical Trials

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Start date: January 1, 2002
Phase: Phase 3
Study type: Interventional

Definitive chemoradiotherapy is the standard of care in unresectable esophageal or esophagogastric cancer. A multidisciplinary approach, including chemotherapy and radiotherapy, is important for these patients. Morerover, molecular targeting agents does not show clear efficacy in EC up to now. Nowadays, the pace of development of cancer immunotherapies is accelerating. Clinical evidence of the efficacy of immune checkpoint inhibitors and adoptive immunotherapies herald the onset of a new era in cancer immunotherapy. There have also been recent developments to provide a promising frontier in extending the use of immunotherpay or targeting agents to radiotherapy. The purpose of this study was to explore the optimal treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients with unresectable esophageal or esophagogastric junction cancer.

NCT ID: NCT04675138 Recruiting - Gastric Cancer Clinical Trials

Development of a Clinical Decision Support System With Artificial Intelligence for Cancer Care

Start date: August 20, 2020
Phase:
Study type: Observational

Clinical Decision Support Systems (CDSSs) to augment clinical care and decision making. These are platforms which aim to improve healthcare delivery by enhancing medical decisions with targeted clinical knowledge, patient information, and other health information. In view of the benefit of developing a CDSS, we sought to develop an alternative CDSS for oncologic therapy selection through a partnership with Ping An Technology (Shenzhen, China), beginning with gastric and oesophagal cancer. This would be done in a piecemeal fashion, with the prototype platform utilizing only international guidelines and high-quality published evidence from journals to arrive at case-specific treatment recommendations. This platform would then be evaluated by comparing its recommendations with that from the multidisciplinary tumour boards of several tertiary care institutions to determine the concordance rate.

NCT ID: NCT03211377 Recruiting - Clinical trials for Esophagogastric Junction Cancer

Chemotherapy for Potentially Resectable Locally Advanced Esophagogastric Junction Carcinoma

Start date: March 29, 2017
Phase: N/A
Study type: Observational

This is a non-interventional study to observe the safety and efficiency of chemotherapy for potentially resectable locally advanced esophagogastric junction

NCT ID: NCT03139487 Recruiting - Pancreatic Cancer Clinical Trials

A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism

PRIORITY
Start date: August 7, 2017
Phase: Phase 2
Study type: Interventional

This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper gastrointestinal, hepatobiliary, or pancreatic cancer, based on a group sequential design. Enrolled patients will be randomized in a 1:1 ratio. Patients will be stratified by performance status, type of cancer, chemotherapy and medical centers.

NCT ID: NCT02988921 Recruiting - Esophagus Cancer Clinical Trials

MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy

Start date: October 2016
Phase: N/A
Study type: Interventional

Magnetic resonance imaging (MRI) with functional features of diffusion weighted imaging (DWI) are advancing imaging technologies that have potential to overcome limitations of conventional staging methods, radiation treatment planning and the assessment of tumor response in esophageal or esophagogastric cancer. This study aimed to explore the value of MRI for the prediction of tumor response to chemoradiotherapy and accurate target volume delineation as compared to CT simulation for patients with unresectable or potentially resectable esophageal or esophagogastric cancer undergoing chemoradiotherapy. The average CT texture features are also extracted before and during treatment to establish a model to predict the prognosis or side effects (e.g. radiation pneumonitis or esophagitis) of patients.